文拉法辛在慢性阻塞性肺疾病伴焦虑抑郁治疗中的临床应用

Clinical application of venlafaxine in the treatment of chronic obstructive pulmonary disease complicated with anxiety and depression

目的研究文拉法辛在慢性阻塞性肺疾病(COPD)伴焦虑抑郁治疗中的临床应用。方法 60例慢性阻塞性肺疾病伴焦虑抑郁患者作为研究对象,严格按照随机原则将其分为对照组与观察组,各30例。给予对照组患者常规治疗法进行治疗,而观察组患者则在常规治疗的基础上服用文拉法辛同时进行治疗。对比并分析两组患者的治疗效果。结果治疗前两组生活质量评分比较差异无统计学意义(P>0.05);治疗后两组生活质量评分均高于治疗前,且观察组生活质量评分(92.47±3.11)分高于对照组(80.84±2.55)分,差异均具有统计学意义(P<0.05)。治疗前两组汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)评分比较差异均无统计学意义(P>0.05);治疗后两组HAMA、HAMD评分均低于治疗前,且观察组HAMA、HAMD评分(6.03±1.58)、(9.15±2.04)分均低于对照组(13.78±2.59)、(14.56±2.92)分,差异均具有统计学意义(P<0.05)。结论文拉法辛有利于治疗慢性阻塞性肺疾病伴焦虑抑郁,且治疗效果较为显著,值得临床推广使用。

Objective To study the clinical application of venlafaxine in the treatment of chronic obstructive pulmonary disease （COPD） complicated with anxiety and depression. Methods A total of 60 chronic obstructive pulmonary disease patients with anxiety and depression as study subjects were randomly divided into control group and observation group, with 30 eases in each group. The control group was treated with conventional therapy, and the observation group was treated with venlafaxine on the basis of conventional therapy. Treatment effect in two groups was compared and analyzed in two groups. Results Before treatment, both groups had no statistically significant difference in quality of life score （P〉0.05）. After treatment, both groups had higher quality of life score than before treatment, and the observation group had higher quality of life score as （92.47 ± 3.11） points than （80.84 ± 2.55） points in the control group. Their difference was statistically significant （P〈0.05）. Before treatment, both groups had no statistically significant difference in Hamilton anxiety scale （HAMA） and the Hamilton depression scale （HAMD） score （P〉0.05）. After treatment, both groups had lower HAMA and HAMD score than before treatment, and the observation group had lower HAMA and HAMD score as （6.03 ± 1.58） and （9.15 ± 2.04） points than （13.78 ± 2.59） and （14.56 ± 2.92） points in the control group. Their difference was statistically significant （P〈0.05）. Conclusion Venlafaxine is beneficial to the treatment of chronic obstructive pulmonary disease associated with anxiety and depression, and the treatment effect is more significant. So it is worthy of clinical promotion and use.